The end of last year was a challenging period for Sanofi but CEO Olivier Brandicourt believes the company is on track with its 2020 strategy, which focuses on reshaping the group's portfolio and sustaining R&D innovation.
Following this trend, divestment of its European generics business is next on the cards as Sanofi continues to cut historical chunks of the company to make